Vedolizumab

[MAF] Vedolizumab (Entyvio) Infusion 300 mg

1. Additional clinical criteria applies
   
   Treatment of adults with moderately to severely active Crohn’s disease who have failed both conventional therapy and anti-TNFα biologics.

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

01/07/2022 Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease

The Ministry of Health’s Drug Advisory Committee has recommended:

• Tofacitinib 5 mg tablet for treating adults with moderately to severely active ulcerative colitis (UC) who have failed conventional therapy and/or anti-TNFα biologics; and

• Vedolizumab 300 mg/vial powder for concentrate for solution for infusion for treating adults with moderately to severely active Crohn’s disease (CD) who have failed both conventional therapy and anti-TNFα biologics.

Subsidy status

[R] Tofacitinib 5 mg tablets and vedolizumab 300 mg/vial powder for concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications.

[R] Tofacitinib and vedolizumab should be used in line with the clinical criteria for initial and continuing prescriptions for patients with UC and CD in the respective MAF checklists.

[R] Listing on MAF will be implemented on 1 July 2022.

[NR] MAF assistance does not apply to any formulations or strengths of ustekinumab for treating CD and UC.

02/01/2019 Vedolizumab for treating ulcerative colitis and Crohn’s disease

[NR] The Ministry of Health’s Drug Advisory Committee has not recommended listing vedolizumab on the Medication Assistance Fund (MAF) for treating ulcerative colitis and Crohn’s disease because of unacceptable cost-effectiveness compared with biosimilar infliximab at the price proposed by the manufacturer.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration